Charles River Laboratories International, Inc. closed at $340.83 on November 13, 2026, a decline of 0.53% over the prior 24 hours. The modest daily pullback came even as the stock's broader momentum remained intact.
Over the past seven days, CRL has climbed 8.95%, and the 30-day performance stands at a gain of 13.97%, reflecting sustained buying interest over the past month. The company's market capitalization is currently $16.42 billion.
The daily dip marks a minor interruption in what has otherwise been a strong stretch for the stock. The gap between the short-term and longer-term trends suggests the single-session retreat is relatively small in context of recent gains.
Charles River Laboratories, which provides drug development and research services, continues to draw attention as reflected in its market valuation. Thursday's slight decline leaves the stock still well above levels seen 30 days prior.



